Physician profile
Christopher Michael Barron
NPI 1477085561
$1,864.73
in general payments reported to CMS, 2019-2025
20 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2021: $363 · 2022: $438 · 2023: $160 · 2024: $218 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $250.55 | 2019-2022 | |
| Dompe US, INC. | $224.56 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $184.53 | 2021-2022 | |
| Biotissue Holdings INC. | $161.82 | 2021-2022 | |
| Glaukos Corporation | $152.82 | 2024-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $150.95 | 2022-2025 | Ryzumvi, Tyrvaya |
| Bausch & Lomb Americas INC. | $129.96 | 2022-2023 | Ic-8 Apthera Iol |
| Aerie Pharmaceuticals, INC. | $120.48 | 2019 | |
| Abbvie INC. | $115.18 | 2022-2025 | |
| Allergan, INC. | $107.94 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $52.96 | 2023 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $47.21 | 2024 | Xdemvy |
| Astellas Pharma US INC | $26.92 | 2024 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $23.63 | 2022 | |
| Sight Sciences, INC. | $22.57 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $21.80 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Mallinckrodt Hospital Products INC. | $21.79 | 2022 | |
| Ocular Therapeutix, INC. | $21.01 | 2023 | Dextenza |
| Harrow Eye, LLC | $15.72 | 2025 | |
| Eyevance Pharmaceuticals LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.